155 related articles for article (PubMed ID: 21885923)
1. Informed consent and immunohistochemistry screening for Lynch syndrome.
Williams JL; Williams MS
Genet Med; 2011 Sep; 13(9):848-9. PubMed ID: 21885923
[No Abstract] [Full Text] [Related]
2. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome.
Chubak B; Heald B; Sharp RR
Genet Med; 2011 Apr; 13(4):356-60. PubMed ID: 21407081
[TBL] [Abstract][Full Text] [Related]
3. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma.
Metcalfe MJ; Petros FG; Rao P; Mork ME; Xiao L; Broaddus RR; Matin SF
J Urol; 2018 Jan; 199(1):60-65. PubMed ID: 28797715
[TBL] [Abstract][Full Text] [Related]
4. [Tumour examination to detect hereditary colorectal cancer].
Hoogerbrugge N; Hermens RP; Nagengast F; Overbeek L; van Krieken HJ; Ligtenberg M
Ned Tijdschr Geneeskd; 2012; 156(42):A4982. PubMed ID: 23075775
[TBL] [Abstract][Full Text] [Related]
5. Population-based molecular screening for Lynch syndrome: implications for personalized medicine.
Ward RL; Hicks S; Hawkins NJ
J Clin Oncol; 2013 Jul; 31(20):2554-62. PubMed ID: 23733757
[TBL] [Abstract][Full Text] [Related]
6. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?
Hall MJ
J Natl Compr Canc Netw; 2010 May; 8(5):606-11. PubMed ID: 20495087
[TBL] [Abstract][Full Text] [Related]
7. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome).
Lynch HT; Lynch JF; Lynch PM
J Natl Cancer Inst; 2007 Feb; 99(4):261-3. PubMed ID: 17312298
[No Abstract] [Full Text] [Related]
8. Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer (HNPCC).
Nallamilli BRR; Hegde M
Curr Protoc Hum Genet; 2017 Jul; 94():10.12.1-10.12.23. PubMed ID: 28696559
[TBL] [Abstract][Full Text] [Related]
9. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
Kravochuck SE; Church JM
ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
[TBL] [Abstract][Full Text] [Related]
10. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
11. Molecular screening of all colorectal tumors diagnosed before age 50 years followed by genetic testing efficiently identifies Lynch syndrome cases.
Jenkins MA; Dowty JG; Hopper JL; Southey MC
Int J Cancer; 2009 Mar; 124(5):x-i. PubMed ID: 19097168
[No Abstract] [Full Text] [Related]
12. Deficient mismatch repair testing in colorectal cancer: more than just screening for Lynch syndrome.
West NP
Colorectal Dis; 2019 Jun; 21(6):621-622. PubMed ID: 31152577
[No Abstract] [Full Text] [Related]
13. On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms.
Dinjens WN; van Leerdam ME; Wagner A
Expert Rev Mol Diagn; 2010 May; 10(4):381-4. PubMed ID: 20465492
[No Abstract] [Full Text] [Related]
14. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
[TBL] [Abstract][Full Text] [Related]
15. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
Tafe LJ
J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
[TBL] [Abstract][Full Text] [Related]
16. [Management of hereditary non-polyposis syndrome (Lynch syndrome)].
Kariv R; Goldberg Y; Soler I; Rosner G; Half E; Moshkowitz M; Vilkin A; Levi Z; Niv Y
Harefuah; 2011 Apr; 150(4):392-6, 416. PubMed ID: 22164924
[TBL] [Abstract][Full Text] [Related]
17. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
[TBL] [Abstract][Full Text] [Related]
18. Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis.
Sciallero S; Sobrero A
J Clin Oncol; 2010 Oct; 28(28):e537; author reply e538. PubMed ID: 20679625
[No Abstract] [Full Text] [Related]
19. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
